271 related articles for article (PubMed ID: 11711492)
1. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
Kolyada AY; Fedtsov A; Madias NE
Hypertension; 2001 Nov; 38(5):1024-9. PubMed ID: 11711492
[TBL] [Abstract][Full Text] [Related]
2. Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappaB pathway.
Nakata S; Tsutsui M; Shimokawa H; Yamashita T; Tanimoto A; Tasaki H; Ozumi K; Sabanai K; Morishita T; Suda O; Hirano H; Sasaguri Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):92-8. PubMed ID: 17082483
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ.
Wagner AH; Schwabe O; Hecker M
Br J Pharmacol; 2002 May; 136(1):143-9. PubMed ID: 11976279
[TBL] [Abstract][Full Text] [Related]
4. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Dichtl W; Dulak J; Frick M; Alber HF; Schwarzacher SP; Ares MP; Nilsson J; Pachinger O; Weidinger F
Arterioscler Thromb Vasc Biol; 2003 Jan; 23(1):58-63. PubMed ID: 12524225
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Alfon J; Guasch JF; Berrozpe M; Badimon L
Atherosclerosis; 1999 Aug; 145(2):325-31. PubMed ID: 10488960
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Kiyono T; Fleck E; Van Herle A; Graf K; Law RE
Eur J Pharmacol; 2003 Feb; 462(1-3):15-23. PubMed ID: 12591091
[TBL] [Abstract][Full Text] [Related]
7. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.
Wagner AH; Gebauer M; Güldenzoph B; Hecker M
Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1784-9. PubMed ID: 12426205
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
Ortego M; Bustos C; Hernández-Presa MA; Tuñón J; Díaz C; Hernández G; Egido J
Atherosclerosis; 1999 Dec; 147(2):253-61. PubMed ID: 10559511
[TBL] [Abstract][Full Text] [Related]
9. Cellular antioxidant effects of atorvastatin in vitro and in vivo.
Wassmann S; Laufs U; Müller K; Konkol C; Ahlbory K; Bäumer AT; Linz W; Böhm M; Nickenig G
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):300-5. PubMed ID: 11834532
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
Li J; Li JJ; He JG; Nan JL; Guo YL; Xiong CM
Cardiovasc Ther; 2010; 28(1):8-14. PubMed ID: 20074254
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin.
Chandrasekar B; Mummidi S; Mahimainathan L; Patel DN; Bailey SR; Imam SZ; Greene WC; Valente AJ
J Biol Chem; 2006 Jun; 281(22):15099-109. PubMed ID: 16554298
[TBL] [Abstract][Full Text] [Related]
12. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.
Ortego M; Hernández AG; Bustos C; Blanco-Colio LM; Hernández-Presa MA; Tuñón J; Egido J
Eur J Pharmacol; 2002 Jul; 448(2-3):113-21. PubMed ID: 12144930
[TBL] [Abstract][Full Text] [Related]
13. HMG-CoA reductase inhibitor enhances inducible nitric oxide synthase expression in rat vascular smooth muscle cells; involvement of the Rho/Rho kinase pathway.
Yamamoto T; Takeda K; Harada S; Nakata T; Azuma A; Sasaki S; Nakagawa M
Atherosclerosis; 2003 Feb; 166(2):213-22. PubMed ID: 12535733
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.
Wassmann S; Laufs U; Bäumer AT; Müller K; Konkol C; Sauer H; Böhm M; Nickenig G
Mol Pharmacol; 2001 Mar; 59(3):646-54. PubMed ID: 11179461
[TBL] [Abstract][Full Text] [Related]
15. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.
Feron O; Dessy C; Desager JP; Balligand JL
Circulation; 2001 Jan; 103(1):113-8. PubMed ID: 11136695
[TBL] [Abstract][Full Text] [Related]
16. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages.
Huang KC; Chen CW; Chen JC; Lin WW
J Biomed Sci; 2003; 10(4):396-405. PubMed ID: 12824699
[TBL] [Abstract][Full Text] [Related]
17. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
Hernández-Perera O; Pérez-Sala D; Navarro-Antolín J; Sánchez-Pascuala R; Hernández G; Díaz C; Lamas S
J Clin Invest; 1998 Jun; 101(12):2711-9. PubMed ID: 9637705
[TBL] [Abstract][Full Text] [Related]
18. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.
Wagner AH; Köhler T; Rückschloss U; Just I; Hecker M
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):61-9. PubMed ID: 10634801
[TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Martínez-González J; Alfón J; Berrozpe M; Badimon L
Atherosclerosis; 2001 Nov; 159(1):27-33. PubMed ID: 11689203
[TBL] [Abstract][Full Text] [Related]
20. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
Parker RA; Huang Q; Tesfamariam B
Atherosclerosis; 2003 Jul; 169(1):19-29. PubMed ID: 12860247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
